

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



23rd October 2024

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street,	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex,
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

## **Ref.:** Intimation under Regulation 29(1)(e) and 42 of the Listing Regulations

## **Subject:** Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 17<sup>th</sup> October 2024, informing you about the Board meeting scheduled on Monday, 28<sup>th</sup> October 2024 to *inter-alia* consider and take on record the unaudited financial results for the second quarter and half year ended 30<sup>th</sup> September 2024.

Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider:

- a. declaration of 1<sup>st</sup> interim dividend for the financial year ending 31<sup>st</sup> March 2025; and
- b. fixation of Wednesday, 6<sup>th</sup> November 2024 as the Record Date for the payment of interim dividend, if declared.

You are requested to please take a note of the same and disseminate to all concerned.

Thanking you,

Yours faithfully,

**Gaurang Shah** Sr. VP – Legal & Company Secretary

Page 1 of 1